TriLink BioTechnologies Headquarters Expansion

Founded in 1996, TriLink BioTechnologies is a global leader in the synthesis of custom RNA, DNA, NTPs and oligonucleotides used throughout the genomics industry. TriLink’s highly modified nucleic acid products are instrumental in the fields of gene and oligonucleotide therapy, gene editing and molecular diagnostics. The company is ISO 9001:2015 certified and operates multiple cGMP suites for manufacturing high-quality nucleic acids.

Construction is underway on two facility expansions, allowing TriLink to add custom plasmid DNA manufacturing as part of our complete mRNA solutions. Additional cGMP suites to support CleanCap^® mRNA capping production will be completed in early 2021.